Restless Legs Syndrome and Erectile Dysfunction: The Dopamine Connection Most Men Never Hear About

The relationship between restless legs syndrome and erectile dysfunction is one of the more counterintuitive findings in men's health research. A condition defined by an irresistible urge to move the legs at night does not obviously belong in a discussion of erectile physiology. Yet a large prospective cohort, a recent case-control study using validated instruments, and a growing body of mechanistic work all point in the same direction: men with restless legs syndrome carry a measurably higher burden of erectile dysfunction, and the overlap appears to run through shared dopaminergic, iron-dependent, and vascular pathways rather than through coincidence alone.

Restless Legs Syndrome Is a Brain Disorder That Presents in the Legs

Restless legs syndrome, also called Willis-Ekbom disease, is diagnosed clinically. The International Restless Legs Syndrome Study Group consensus criteria require an urge to move the legs, usually accompanied by uncomfortable sensations; symptoms that begin or worsen during rest or inactivity; partial or total relief with movement; a clear circadian pattern with symptoms worse in the evening or night; and the exclusion of mimics such as leg cramps, positional discomfort, or habitual foot tapping ^[1].

Nothing in that definition is orthopaedic. The urge originates centrally, and the leg is simply where it is felt. This matters for the sexual health conversation, because the central nervous system structures implicated in restless legs syndrome are not confined to motor control. They overlap with the circuitry that initiates erection.

Restless legs syndrome is also chronically underdiagnosed. Men frequently describe it as poor sleep, twitchy legs, or simple insomnia, and it is often managed as a nuisance rather than investigated as a neurological condition with systemic associations.

What the Prospective Data Show

The strongest evidence linking restless legs syndrome and erectile dysfunction comes from the Health Professionals Follow-up Study. Li and colleagues followed 10,394 men with a mean age of 63.4 years over six years, assessing restless legs syndrome in 2002 using the standardised IRLSSG questions and erectile function by questionnaire in 2000, 2004, and 2008. Across follow-up they identified 1,633 incident cases of erectile dysfunction ^[2].

Men with restless legs syndrome were significantly more likely to develop erectile dysfunction, with a relative risk of 1.38 (95% CI 1.14–1.68; P = 0.001) after adjustment for age, body mass index, smoking, physical activity, snoring status, and other sleep disorders. The association followed a dose-response pattern: the more frequent the restless legs symptoms, the higher the risk of erectile dysfunction (P for trend = 0.001). The authors also noted that combinations of other sleep disorders with restless legs syndrome further increased risk ^[2].

The adjustment for other sleep disorders matters. It suggests the signal is not simply a proxy for sleep apnoea or general sleep loss.

More recent work using validated severity instruments points the same way. Kim and colleagues compared 47 newly diagnosed, treatment-naive men with moderate-to-severe restless legs syndrome against 80 age-matched men without sleep disorders. Mean IIEF-5 scores were significantly lower in the restless legs group (15.32 ± 5.89 versus 18.76 ± 5.96; p = 0.001), and the prevalence of erectile dysfunction defined as IIEF-5 at or below 21 was 78.7% versus 52.5%. In multiple regression, age (β = −0.35, p = 0.006) and sleep quality (β = −0.29, p = 0.018) were independent predictors of erectile dysfunction severity within the restless legs cohort ^[3].

The literature is not unanimous, and the discordant study is worth reading carefully. Kurt and colleagues compared 50 men with restless legs syndrome to 50 controls matched on age, body mass index, hypertension history, and total testosterone, with no diabetes in either group. Overall erectile dysfunction prevalence was 52% versus 34%, which did not reach statistical significance (p = 0.069). However, moderate and severe erectile dysfunction was significantly more common in the restless legs group (p = 0.045), and premature ejaculation was clearly more prevalent (54% versus 34%; p = 0.008) ^[4].

Read together, these studies suggest the association is real but graded: restless legs syndrome tracks more strongly with severe erectile dysfunction than with mild symptoms, and it also tracks with ejaculatory dysfunction.

The Dopamine and Brain Iron Hypothesis

The mechanistic case rests largely on dopamine. Restless legs syndrome is understood as a disorder of altered brain iron homeostasis with downstream dopaminergic dysfunction. Iron is a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis, and regional brain iron insufficiency — which can exist despite normal peripheral iron indices — appears to drive a compensatory, circadian-modulated disturbance in dopaminergic signalling ^[5].

Dopamine is not incidental to erection. Central dopaminergic pathways projecting to the hypothalamic paraventricular nucleus are pro-erectile, and this pathway is the reason apomorphine, a non-selective dopamine agonist, was developed and marketed as a centrally acting treatment for erectile dysfunction rather than as a vascular agent. If restless legs syndrome reflects a chronic perturbation of the same neurotransmitter system, an association with impaired central initiation of erection is biologically coherent rather than surprising.

This also helps explain the premature ejaculation signal in the Kurt data, since ejaculatory timing is under substantial dopaminergic and serotonergic control.

Sleep Fragmentation, Testosterone, and Nocturnal Erections

The second mechanism is more prosaic: restless legs syndrome destroys sleep architecture. Symptoms peak in the evening and night, delay sleep onset, and fragment sleep once it begins.

Testosterone release in men is strongly sleep-dependent, rising with sleep onset and peaking during the night. In a controlled study, one week of sleep restricted to roughly five hours per night reduced daytime testosterone levels in young healthy men by approximately 10–15% ^[6]. Restless legs syndrome imposes a chronic version of that stimulus, and it does so in men who are typically decades older and already on the downslope of age-related androgen decline.

Sleep loss also removes nocturnal penile tumescence. Erections during REM sleep are thought to serve a trophic function, maintaining cavernosal oxygenation and limiting fibrotic remodelling of erectile tissue. Fewer REM cycles means fewer nocturnal erections, and over years this may contribute to structural change rather than merely functional complaint.

Cho and Duffy, reviewing the intersection of sleep medicine and urology, place restless legs syndrome alongside obstructive sleep apnoea, insomnia, and shift work disorder as sleep conditions associated with erectile dysfunction and other urological problems, and argue that sleep should be treated as a third pillar of health alongside diet and exercise when evaluating sexual dysfunction ^[7]. A 2026 meta-analysis of sleep disorders and male sexual dysfunction has since pooled hormonal and IIEF outcomes across this literature, with subgroup analysis separating obstructive sleep apnoea from shift work sleep disorder ^[8].

The Shared Vascular Denominator

There is a third thread. In the Sleep Heart Health Study, Winkelman and colleagues reported an association between restless legs syndrome and prevalent cardiovascular and coronary artery disease, with the relationship strongest among participants reporting more frequent and more severe symptoms ^[9]. A systematic review of restless legs syndrome in the context of major comorbidities similarly positions it as a condition that clusters with cardiovascular, renal, and metabolic disease rather than existing in isolation ^[10].

Erectile dysfunction is itself an early marker of endothelial dysfunction, typically preceding overt coronary events by several years because the cavernosal arteries are narrower than the coronaries and register atherosclerotic change sooner. If restless legs syndrome is a marker of cardiovascular risk, and erectile dysfunction is a marker of cardiovascular risk, some of their statistical overlap is simply two symptoms of one underlying vascular process.

That does not diminish the finding. It sharpens what should be done about it.

What This Means in Practice

For a man experiencing both problems, the practical implications are concrete.

Restless legs symptoms deserve a named diagnosis rather than being absorbed into a general complaint of poor sleep. Serum ferritin and transferrin saturation are routinely checked, because iron repletion is a first-line consideration in restless legs syndrome even when ferritin sits within the conventional reference range. A medication review matters too: sedating antihistamines, several antidepressants, and dopamine-antagonist antiemetics can all worsen restless legs symptoms, and some of the same agents independently impair erectile function.

Dopamine agonist therapy for restless legs syndrome carries its own considerations, including augmentation with long-term use and a recognised risk of impulse control disorders, which is why current practice has shifted toward alpha-2-delta ligands in many patients. These are decisions for a treating clinician, not a self-directed experiment.

Finally, erectile dysfunction in a man with restless legs syndrome should not be assumed to be psychogenic simply because he is tired and frustrated. The data suggest a neurological and vascular substrate worth evaluating on its own terms. Further reading on the vascular and neurological contributors to erectile function is available in our medical library.

Conclusion

Restless legs syndrome and erectile dysfunction are linked by more than shared inconvenience. A six-year prospective cohort found a 38% higher relative risk of incident erectile dysfunction in affected men with a clear dose-response gradient, case-control data using the IIEF-5 found substantially lower scores and higher prevalence, and the discordant study still found more severe erectile dysfunction and more premature ejaculation in the restless legs group. Dopaminergic dysfunction driven by altered brain iron handling, chronic sleep fragmentation with its hormonal and trophic consequences, and a shared cardiovascular risk profile together provide a plausible explanation. Clinical studies suggest that men presenting with one of these conditions warrant evaluation for the other, and some men experience meaningful improvement in sexual function when the underlying sleep disorder is properly identified and treated.

If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans starting with a free online assessment at questionnaire.getonyxmd.com. Formulations such as VAST, which combines a centrally acting dopamine agonist with two PDE5 inhibitors, are prescribed only after a licensed physician reviews your history.

---

These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.

References

1. Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, Zucconi M, Ferri R, Trenkwalder C, Lee HB; International Restless Legs Syndrome Study Group. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—history, rationale, description, and significance. Sleep Medicine. 2014;15(8):860-873. doi:10.1016/j.sleep.2014.03.025
2. Li Y, Batool-Anwar S, Kim S, Rimm EB, Ascherio A, Gao X. Prospective study of restless legs syndrome and risk of erectile dysfunction. American Journal of Epidemiology. 2013;177(10):1097-1105. doi:10.1093/aje/kws364
3. Kim GY, Kim KT, Cho YW. Association between restless legs syndrome and erectile dysfunction in Korean men: A cross-sectional study. Sleep Medicine. 2025;131:106509. doi:10.1016/j.sleep.2025.106509
4. Kurt O, Yazici CM, Alp R, Sancak EB, Topcu B. Is it only a sleeping disorder or more? Restless legs syndrome and erectile function. Scandinavian Journal of Urology. 2016;50(5):392-395. doi:10.1080/21681805.2016.1195443
5. Earley CJ, Connor J, Garcia-Borreguero D, Jenner P, Winkelman J, Zee PC, Allen R. Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease). Sleep Medicine. 2014;15(11):1288-1301. doi:10.1016/j.sleep.2014.05.009
6. Leproult R, Van Cauter E. Effect of 1 week of sleep restriction on testosterone levels in young healthy men. JAMA. 2011;305(21):2173-2174. doi:10.1001/jama.2011.710
7. Cho JW, Duffy JF. Sleep, sleep disorders, and sexual dysfunction. The World Journal of Men's Health. 2019;37(3):261-275. doi:10.5534/wjmh.180045
8. Almurayyi M, Alshahrani ST, Alshardi WI, Alshahrani MA, Asiri AA, ALGhamdi KM, Alhifthi MA, Alshahrani M, Safar O. Sleep disorders and male sexual dysfunction: a meta-analysis of hormonal and erectile outcomes. Archivio Italiano di Urologia e Andrologia. 2026. doi:10.4081/aiua.2026.15659
9. Winkelman JW, Shahar E, Sharief I, Gottlieb DJ. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology. 2008;70(1):35-42. doi:10.1212/01.wnl.0000287072.93277.c9
10. Trenkwalder C, Allen R, Högl B, Paulus W, Winkelmann J. Restless legs syndrome associated with major diseases: A systematic review and new concept. Neurology. 2016;86(14):1336-1343. doi:10.1212/WNL.0000000000002542